New-Onset Diabetes Mellitus in COVID-19: A Scoping Review.

Coronavirus disease 2019 Diabetes mellitus Hyperglycemia New-onset diabetes New-onset hyperglycemia Newly diagnosed diabetes Prediabetes Severe acute respiratory syndrome coronavirus-2 infection

Journal

Diabetes therapy : research, treatment and education of diabetes and related disorders

ISSN: 1869-6953

Titre abrégé: Diabetes Ther

Pays: United States

ID NLM: 101539025

Informations de publication

Date de publication:
26 Sep 2023

Historique:

received: 05 07 2023

accepted: 15 08 2023

pubmed: 26 9 2023

medline: 26 9 2023

entrez: 26 9 2023

Statut: aheadofprint

Résumé

The coronavirus disease 2019 (COVID-19) pandemic became superimposed on the pre-existing obesity and diabetes mellitus (DM) pandemics. Since COVID-19 infection alters the metabolic equilibrium, it may induce pathophysiologic mechanisms that potentiate new-onset DM, and we evaluated this issue. A systematic review of the literature published from the 1 January 2020 until the 20 July 2023 was performed (PROSPERO registration number CRD42022341638). We included only full-text articles of both human clinical and randomized controlled trials published in English and enrolling adults (age > 18 years old) with ongoing or preceding COVID-19 in whom hyperglycemia was detected. The search was based on the following criteria: "(new-onset diabetes mellitus OR new-onset DM) AND (COVID-19) AND adults". Articles on MEDLINE (n = 70) and the Web of Science database (n = 16) were included and analyzed by two researchers who selected 20 relevant articles. We found evidence of a bidirectional relationship between COVID-19 and DM. This link operates as a pathophysiological mechanism supported by epidemiological data and also by the clinical and biological findings obtained from the affected individuals. The COVID-19 pandemic raised the incidence of DM through different pathophysiological and psychosocial factors.

Identifiants

DOI: 10.1007/s13300-023-01465-7 PMID: 37751143

pubmed: 37751143

doi: 10.1007/s13300-023-01465-7

pii: 10.1007/s13300-023-01465-7

doi:

Types de publication

Journal Article Review

Langues

eng

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Références

Worldometer. COVID Live: coronavirus statistics. Available from: https://www.worldometers.info/coronavirus/ . Cited 17 Dec 2022.

Ghosh A, Anjana RM, Shanthi Rani CS, Jeba Rani S, Gupta R, Jha A, et al. Glycemic parameters in patients with new-onset diabetes during COVID-19 pandemic are more severe than in patients with new-onset diabetes before the pandemic: NOD COVID India Study. Diabetes Metab Syndr. 2021;15:215–20.

doi: 10.1016/j.dsx.2020.12.033 pubmed: 33450530

Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11–30.

doi: 10.1038/s41574-020-00435-4 pubmed: 33188364

Salmen T, Pietroşel VA, Mihai BM, Bica IC, Teodorescu C, Păunescu H, Coman OA, Mihai DA, Pantea SA. Non-insulin novel antidiabetic drugs mechanisms in the pathogenesis of COVID-19. Biomedicines. 2022;10(10):2624.

doi: 10.3390/biomedicines10102624 pubmed: 36289885 pmcid: 9599217

Palano MT, Cucchiara M, Gallazzi M, Riccio F, Mortara L, Gensini GF, Spinetti G, Ambrosio G, Bruno A. When a friend becomes your enemy: natural killer cells in atherosclerosis and atherosclerosis-associated risk factors. Front Immunol. 2022;12:798155. https://doi.org/10.3389/fimmu.2021.798155 .

doi: 10.3389/fimmu.2021.798155 pubmed: 35095876 pmcid: 8793801

Zafarani A, Razizadeh MH, Pashangzadeh S, Amirzargar MR, Taghavi-Farahabadi M, Mahmoudi M. Natural killer cells in COVID-19: from infection, to vaccination and therapy. Future Virol. 2023. https://doi.org/10.2217/fvl-2022-0040

Kapoor N, Kalra S, Al Mahmeed W, et al. The dual pandemics of COVID-19 and obesity: bidirectional impact. Diabetes Therapy. 2022;13(10):1723–36.

Filippi CM, Von Herrath MG. Viral trigger for type 1 diabetes: pros and cons. Diabetes. 2008;57:2863–71.

doi: 10.2337/db07-1023 pubmed: 18971433 pmcid: 2570378

Fabiani S, Fallahi P, Ferrari SM, Miccoli M, Antonelli A. Hepatitis C virus infection and development of type 2 diabetes mellitus: systematic review and meta-analysis of the literature. Rev Endocr Metab Disord. 2018;19:405–20.

doi: 10.1007/s11154-017-9440-1 pubmed: 29322398

Gupta RD, Atri A, Mondal S, Bhattacharjee A, Garai R, Hazra AK, et al. Characterizing progressive beta-cell recovery after new-onset DKA in COVID-19 provoked A-β+ KPD (ketosis-prone diabetes): a prospective study from Eastern India. J Diabetes Compl. 2022;36: 108100.

doi: 10.1016/j.jdiacomp.2021.108100

Pantea Stoian A, Pricop-Jeckstadt M, Pana A, Ileanu BV, Schitea R, Geanta M, Catrinoiu D, Suceveanu AI, Serafinceanu C, Pituru S, Poiana C, Timar B, Nitipir C, Parvu S, Arsene A, Mazilu L, Toma A, Hainarosie R, Ceriello A, Rizzo M, Jinga V. Death by SARS-CoV 2: a Romanian COVID-19 multi-centre comorbidity study. Sci Rep. 2020;10:21613.

doi: 10.1038/s41598-020-78575-w pubmed: 33303885 pmcid: 7730445

Ammar A, Brach M, Trabelsi K, Chtourou H, Boukhris O, Masmoudi L, et al. Effects of COVID-19 home confinement on eating behaviour and physical activity: results of the ECLB-COVID19 international online survey. Nutrients. 2020;12:1583.

doi: 10.3390/nu12061583 pubmed: 32481594 pmcid: 7352706

Zugravu C, Salmen T, Ducu I, Mihai BM, Dima V, Berceanu C, Bohiltea AT, Smaranda N, Bacalbasa N, Balescu I, Bohiltea RE. The influence of the COVID-19 pandemic on lifestyle—a pilot study. Romanian J Infect Dis. 2021;24(4):190–7.

Khunti K, Valabhji J, Misra S. Diabetes and the COVID-19 pandemic. Diabetologia. 2022;23:1–12. https://doi.org/10.1007/s00125-022-05833-z .

doi: 10.1007/s00125-022-05833-z

Mithal A, Jevalikar G, Sharma R, Singh A, Farooqui KJ, Mahendru S, et al. High prevalence of diabetes and other comorbidities in hospitalized patients with COVID-19 in Delhi, India, and their association with outcomes. Diabetes Metab Syndr. 2021;15:169–75.

doi: 10.1016/j.dsx.2020.12.029 pubmed: 33360081

Gentile S, Strollo F, Mambro A, Ceriello A. COVID-19, ketoacidosis and new-onset diabetes: are there possible cause and effect relationships among them? Diabetes Obes Metab. 2020;22:2507–8.

doi: 10.1111/dom.14170 pubmed: 32790021 pmcid: 7436911

Ghash A, Misra A. Marked hyperglycemia and ketosis in a non-obese patient with new-onset diabetes and very mild COVID-19 symptoms: a case report. Diabetes Metab Syndr. 2021;15:213–4.

doi: 10.1016/j.dsx.2020.12.036

Suwanwongse K, Shabarek N. Newly diagnosed diabetes mellitus, DKA, and COVID-19: causality or coincidence? A report of three cases. J Med Virol. 2021;93:1150–3.

doi: 10.1002/jmv.26339 pubmed: 32706395

Reddy PK, Kuchay MS, Mehta Y, Mishra SK. Diabetic ketoacidosis precipitated by COVID-19: a report of two cases and review of the literature. Diabetes Metab Syndr. 2020;14:1459–62.

doi: 10.1016/j.dsx.2020.07.050 pubmed: 32771918 pmcid: 7395228

Boddu SK, Aurangabadkar G, Kuchay MS. New onset diabetes, type 1 diabetes and COVID-19. Diabetes Metab Syndr. 2020;14:2211–7.

doi: 10.1016/j.dsx.2020.11.012 pubmed: 33395782 pmcid: 7669477

Sathish T, Chandrika Anton M. Newly diagnosed diabetes in patients with mild to moderate COVID-19. Diabetes Metab Syndr. 2021;15:569–71.

doi: 10.1016/j.dsx.2021.02.034 pubmed: 33706188 pmcid: 7925231

Notkins AL, Lernmark A. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest. 2001;108(9):1247–52. https://doi.org/10.1172/JCI14257 .

doi: 10.1172/JCI14257 pubmed: 11696564 pmcid: 209446

Cariou B, Pichelin M, Goronflot T, Gonfroy C, Marre M, Raffaitin-Cardin C, et al. Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: results from the CORONADO study. Diabetes Res Clin Pract. 2021;175: 108695.

doi: 10.1016/j.diabres.2021.108695 pubmed: 33577905 pmcid: 7872857

Qeadan F, Tingey B, Egbert J, Pezzolesi MG, Burge MR, Peterson KA, et al. The associations between COVID-19 diagnosis, type 1 diabetes, and the risk of diabetic ketoacidosis: a nationwide cohort from the US using the Cerner Real-World Data. PLoS ONE. 2022;17: e0266809.

doi: 10.1371/journal.pone.0266809 pubmed: 35439266 pmcid: 9017888

Sane AH, Mekonnen MS, Tsegaw MG, Zewde WC, Mesfin EG, Beyene HA, Ashine TM, Tiruneh KG, Mengistie MA. New onset of diabetes mellitus and associated factors among COVID-19 patients in COVID-19 care centers, Addis Ababa, Ethiopia 2022. J Diabetes Res. 2022;12(2022):9652940. https://doi.org/10.1155/2022/9652940 .

Keerthi BY, Sushmita G, Khan EA, Thomas V, Cheryala V, Shah C, Kumar GR, Haritha V. New onset diabetes mellitus in post-COVID-19 patients. J Family Med Prim Care. 2022;11(10):5961–8. https://doi.org/10.4103/jfmpc.jfmpc_316_22 .

doi: 10.4103/jfmpc.jfmpc_316_22 pubmed: 36618178 pmcid: 9810898

Alkhemeiri A, Al Zaabi S, Lakshmanan J, El-Khatib Z, Awofeso N. COVID-19 case management outcomes amongst diabetes and hypertensive patients in the United Arab Emirates: a prospective study. Int J Environ Res Public Health. 2022;19:15967. https://doi.org/10.3390/ijerph192315967 .

doi: 10.3390/ijerph192315967 pubmed: 36498037 pmcid: 9738357

Naveed Z, Velásquez García HA, Wong S, et al. Association of COVID-19 infection with incident diabetes. JAMA Netw Open. 2023;6(4): e238866. https://doi.org/10.1001/jamanetworkopen.2023.8866 .

doi: 10.1001/jamanetworkopen.2023.8866 pubmed: 37071420 pmcid: 10114057

Choi JH, Kim KM, Song K, Seo GH. Risk for newly diagnosed type 2 diabetes mellitus after COVID-19 among Korean adults: a nationwide matched cohort study. Endocrinol Metab (Seoul). 2023;38(2):245–52. https://doi.org/10.3803/EnM.2023.1662 .

Birabaharan M, Kaelber DC, Pettus JH, Smith DM. Risk of new-onset type 2 diabetes in 600 055 people after COVID-19: A cohort study. Diabetes Obes Metab. 2022;24(6):1176–9. https://doi.org/10.1111/dom.14659 .

Sharma A, Misra-Hebert AD, Mariam A, Milinovich A, Onuzuruike A, Koomson W, Kattan MW, Pantalone KM, Rotroff DM. Impacts of COVID-19 on glycemia and risk of diabetic ketoacidosis. Diabetes. 2023;72(5):627–37. https://doi.org/10.2337/db22-0264 .

doi: 10.2337/db22-0264 pubmed: 36107493

Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10(5):311–21. https://doi.org/10.1016/S2213-8587(22)00044-4 .

doi: 10.1016/S2213-8587(22)00044-4 pubmed: 35325624 pmcid: 8937253

Filip R, Anchidin-Norocel L, Gheorghita R, Savage WK, Dimian M. Changes in dietary patterns and clinical health outcomes in different countries during the SARS-CoV-2 pandemic. Nutrients. 2021;13(10):3612. https://doi.org/10.3390/nu13103612 .

doi: 10.3390/nu13103612 pubmed: 34684615 pmcid: 8539259

Sathish T, Tapp RJ, Cooper ME, Zimmet P. Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes. Diabetes Metab. 2021;47(2):101204. https://doi.org/10.1016/j.diabet.2020.10.002 .

doi: 10.1016/j.diabet.2020.10.002 pubmed: 33129968

Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight. 2019;4: e131774.

doi: 10.1172/jci.insight.131774 pubmed: 31550243 pmcid: 6824443

Fadini GP, Morieri ML, Boscari F, Fioretto P, Maran A, Busetto L, et al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract. 2020;168: 108374.

doi: 10.1016/j.diabres.2020.108374 pubmed: 32805345 pmcid: 7428425

Katsiki N, Gómez-Huelgas R, Mikhailidis DP, Pérez-Martínez P. Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers. Int J Clin Pract. 2021;75(11): e14833.

doi: 10.1111/ijcp.14833 pubmed: 34510676

Fuso L, Pitocco D, Antonelli-Incalzi R. Diabetic lung, an underrated complication from restrictive functional pattern to pulmonary hypertension. Diabetes Metab Res Rev. 2019;35: e3159.

doi: 10.1002/dmrr.3159 pubmed: 30909316

D’Souza D, Empringham J, Pechlivanoglou P, Uleryk EM, Cohen E, Shulman R. Incidence of diabetes in children and adolescents during the COVID-19 pandemic: a systematic review and meta-analysis. JAMA Netw Open. 2023;6(6):e2321281. https://doi.org/10.1001/jamanetworkopen.2023.21281 .

Unsworth R, Wallace S, Oliver NS, Yeung S, Kshirsagar A, Naidu H, Kwong RMW, Kumar P, Logan KM. New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K. Diabetes Care. 2020;43(11):e170–1. https://doi.org/10.2337/dc20-1551 .

Vlad A, Serban V, Timar R, Sima A, Botea V, Albai O, Timar B, Vlad M. Increased incidence of type 1 diabetes during the COVID-19 pandemic in Romanian children. Medicina (Kaunas). 2021;57(9):973. https://doi.org/10.3390/medicina5709097342 .

Brooks D, Schulman-Rosenbaum R, Griff M, Lester J, Low Wang CC. Glucocorticoid-induced hyperglycemia including dexamethasone-associated hyperglycemia in COVID-19 infection: a systematic review. Endocr Pract. 2022;28:1166–77.

doi: 10.1016/j.eprac.2022.07.014 pubmed: 35940469 pmcid: 9354392

Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 (DARE-19): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9:586–94.

doi: 10.1016/S2213-8587(21)00180-7 pubmed: 34302745 pmcid: 8294807

Sasaki H, Itoh A, Watanabe Y, Nakajima Y, Saisho Y, Irie J, et al. Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: a case report. J Diabetes Investig. 2022;13:1105–8.

doi: 10.1111/jdi.13757 pubmed: 35088548 pmcid: 9153841

Sasaki K, Morioka T, Okada N, Natsuki Y, Kakutani Y, Ochi A, et al. New-onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination: a case report. J Diabetes Investig. 2022;13:1286–946.

doi: 10.1111/jdi.13771 pubmed: 35167186 pmcid: 9114923

Ali H, Alterki A, Sindhu S.Alahmad B, Hammad M, Al-Sabah S, et al. Robust antibody levels in both diabetic and non-diabetic individuals after BNT162b2 mRNA COVID-19 vaccination. Front Immunol. 2021;12:752233.

Sourij C, Tripolt NJ, Aziz F, Aberer F, Forstner P, Obermayer AM, et al. Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: the prospective COVAC-DM cohort study. Diabetes Obes Metab. 2022;24:849–58.

doi: 10.1111/dom.14643 pubmed: 34984802 pmcid: 9303917

Chourasia P, Goyal L, Kansal D, Roy S, Singh R, Mahata I, Sheikh AB, Shekhar R. Risk of new-onset diabetes mellitus as a post-COVID-19 condition and possible mechanisms: a scoping review. J Clin Med. 2023;12:1159.

Kwan AC, Ebinger JE, Botting P, Navarrette J, Claggett B, Cheng S. Association of COVID-19 vaccination with risk for incident diabetes after COVID-19 infection. JAMA Netw Open. 2023;6(2): e2255965. https://doi.org/10.1001/jamanetworkopen.2022.5596550 .

doi: 10.1001/jamanetworkopen.2022.5596550 pubmed: 36787145 pmcid: 9929690

Ssentongo P, Zhang Y, Witmer L, et al. Association of COVID-19 with diabetes: a systematic review and meta-analysis. Sci Rep. 2022;12:20191.

doi: 10.1038/s41598-022-24185-7 pubmed: 36418912 pmcid: 9684130

Rizvi AA, Kathuria A, Al Mahmeed W, Al-Rasadi K, Al-Alawi K, Banach M, Banerjee Y, Ceriello A, Cesur M, Cosentino F, et al. CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO). Post-COVID syndrome, inflammation, and diabetes. J Diabetes Complicat. 2022;36(11):108336.

Lo Presti E, Nuzzo D, Al Mahmeed W, et al. CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO). Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health. Biochim Biophys Acta Mol Basis Dis. 2022;1868(12):166559.

doi: 10.1016/j.bbadis.2022.166559 pubmed: 36174875 pmcid: 9510069

Zanoli L, Gaudio A, Mikhailidis DP, Katsiki N, Castellino N, Lo Cicero L, Geraci G, Sessa C, Fiorito L, Marino F, et al. Methuselah Study Group. Vascular dysfunction of COVID-19 is partially reverted in the long-term. Circ Res. 2022;130(9):1276–85.

doi: 10.1161/CIRCRESAHA.121.320460 pubmed: 35345906

Giorgino F, Bhana S, Czupryniak L, Dagdelen S, Galstyan GR, Janež A, Lalić N, Nouri N, Rahelić D, Stoian AP, Raz I. Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa. Diabetes Res Clin Pract. 2021;172:108617.

Katsiki N, Banach M, Mikhailidis DP. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. Arch Med Sci. 2020;16(3):485–9.

doi: 10.5114/aoms.2020.94503 pubmed: 32399093 pmcid: 7212217

Billings FT 4th, Pretorius M, Siew ED, Yu C, Brown NJ. Early postoperative statin therapy is associated with a lower incidence of acute kidney injury after cardiac surgery. J Cardiothorac Vasc Anesth. 2010;24(6):913–20. https://doi.org/10.1053/j.jvca.2010.03.024 .

doi: 10.1053/j.jvca.2010.03.024 pubmed: 20599398 pmcid: 2992577

Mazilu L, Katsiki N, et al. Thrombosis and haemostasis challenges in COVID-19—therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions—a mini review. Food Chem Toxicol. 2021;148: 111974.

Wihandani DM, Purwanta MLA, Mulyani WRW, Putra IWAS, Supadmanaba IGP. New-onset diabetes in COVID-19: The molecular pathogenesis. Biomedicine (Taipei). 2023;13(1):3–12. https://doi.org/10.37796/2211-8039.1389 .

doi: 10.37796/2211-8039.1389 pubmed: 37168726

Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–90.

doi: 10.1007/s00134-020-05985-9 pubmed: 32125455 pmcid: 7079879

Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol. 2020;18(9):2128–30.

doi: 10.1016/j.cgh.2020.04.040 pubmed: 32334082 pmcid: 7194639

Al Mahmeed W, Al-Rasadi K, Banerjee Y, Ceriello A, Cosentino F, Galia M, Goh SY, Kempler P, Lessan N, Papanas N, Rizvi AA, Santos RD, Stoian AP, Toth PP, Rizzo M. CArdiometabolic Panel of International experts on Syndemic COVID-19 (CAPISCO). Promoting a syndemic approach for cardiometabolic disease management during COVID-19: The CAPISCO International Expert Panel. Front Cardiovasc Med. 2021;8:787761.

Popovic DS, Papanas N, Koufakis T, Kotsa K, Al Mahmeed W, Al-Rasadi K, et al. Glucometabolic perturbations in type 2 diabetes mellitus and coronavirus disease 2019: causes, consequences, and how to counter them using novel antidiabetic drugs. Exp Clin Endocrinol Diabetes. 2023;131(5):260–267. https://doi.org/10.1055/a-2019-1111 .

Kim SH, Arora I, Hsia DS, Knowler WC, LeBlanc E, Mylonakis E, Pratley R, Pittas AG. New-onset diabetes after COVID-19. J Clin Endocrinol Metab. 2023. https://doi.org/10.1210/clinem/dgad284 .

doi: 10.1210/clinem/dgad284 pubmed: 37850407 pmcid: 10438873

Papachristou S, Stamatiou I, Stoian AP, et al. New-onset diabetes in COVID-19: time to frame its fearful symmetry. Diabetes Ther. 2021;12:461–4.